drugset / Trial / NCT03610880
To Evaluate PK and Safety Profile of Oral MAD of Separately Using TG-2349, DAG181 or Combination in Healthy Chinese Volunteers
Phase 1
Completed
24 enrolled
Dongguan HEC TaiGen Biopharmaceuticals Co., Ltd.
R&G Pharma Studies Co.,Ltd. · collab
RandomizedParallel-groupOpen-labelBasic science
Summary
To evaluate the drug-drug reactions between TG-2349 and DAG181, and the pharmacokinetics and tolerability profile in healthy Chinese volunteers to be the reference for protocol designs of subsequent clinical trials.
Timeline
- Start
- 2017-10-17
- Primary completion
- 2018-02-05
- Completion
- 2018-02-05
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Furaprevir | Small molecule | 400 mg | Oral |
| Subject | Yimitasvir | Small molecule | 200 mg | Oral |
Indications
No indication recorded.